Search Results - "Montero, C"

The immunology of renal cell carcinoma by Díaz-Montero, C. Marcela, Rini, Brian I., Finke, James H.

“…Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises several subtypes with unique characteristics. The most common subtype (~70%…”
Get full text

Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α by Najjar, Yana G, Rayman, Patricia, Jia, Xuefei, Pavicic, Jr, Paul G, Rini, Brian I, Tannenbaum, Charles, Ko, Jennifer, Haywood, Samuel, Cohen, Peter, Hamilton, Thomas, Diaz-Montero, C Marcela, Finke, James

“…Little is known about the association between myeloid-derived suppressor cell (MDSC) subsets and various chemokines in patients with renal cell carcinoma (RCC)…”
Get full text

Is high-intensity interval training more effective on improving cardiometabolic risk and aerobic capacity than other forms of exercise in overweight and obese youth? A meta-analysis by García-Hermoso, A., Cerrillo-Urbina, A. J., Herrera-Valenzuela, T., Cristi-Montero, C., Saavedra, J. M., Martínez-Vizcaíno, V.

“…Summary Background The scientific interest in high‐intensity interval training (HIIT) has greatly increased during recent years. Objective The objective of…”
Get full text

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series by Sun, Lillian, Funchain, Pauline, Song, Jung Min, Rayman, Patricia, Tannenbaum, Charles, Ko, Jennifer, Mcnamara, Michael, Marcela Diaz-Montero, C, Gastman, Brian

“…Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The…”
Get full text

Clinical and Immunologic Features of Germline Pathogenic Variant-Positive Patients with Melanoma by Shen, Alan, Arbesman, Michelle, Lodha, Roshan, Rayman, Patricia, Bungo, Brandon, Ni, Ying, Chan, Timothy, Gastman, Brian, Ko, Jennifer, Diaz-Montero, C Marcela, Arbesman, Joshua, Funchain, Pauline

“…Malignant melanoma represents the most lethal skin cancer with germline predispositions thought to comprise 10% to 15% of all melanoma cases. No studies to…”
Get full text

KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes by Navarro‐Navarro, Paula, Álvarez‐Twose, Iván, Pérez‐Pons, Alba, Henriques, Ana, Mayado, Andrea, García‐Montero, Andrés C., Sánchez‐Muñoz, Laura, González‐López, Oscar, Matito, Almudena, Caldas, Carolina, Jara‐Acevedo, María, Orfao, Alberto

“…Background Current diagnostic algorithms for systemic mastocytosis (SM) rely on the detection of KITD816V in blood to trigger subsequent bone marrow (BM)…”
Get full text

The effect of additions of anticorrosive pigments on the cathodic delamination and wear resistance of an epoxy powder coating by Fernández- Álvarez, M., Hijón-Montero, C., Bautista, A., Velasco, F., de la Fuente, D.

“…The cathodic delamination and wear resistance of epoxy powder coatings were evaluated after adding 3 % (by wt.) of calcium ion exchanged micropigments from…”
Get full text

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy by Diaz-Montero, C. Marcela, Salem, Mohamed Labib, Nishimura, Michael I., Garrett-Mayer, Elizabeth, Cole, David J., Montero, Alberto J.

“…Abnormal accumulation of myeloid-derived suppressor cells (MDSC) is an important mechanism of tumor immune evasion. Cyclophosphamide (CTX) has also been shown…”
Get full text

Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals by González‐de‐Olano, David, Navarro‐Navarro, Paula, Muñoz‐González, Javier I., Sánchez‐Muñoz, Laura, Henriques, Ana, de‐Andrés‐Martín, Ana, Peralta‐Arjonilla, Dolores, Mayado, Andrea, Jara‐Acevedo, María, García‐Montero, Andrés C., Orfao, Alberto, Álvarez‐Twose, Iván

“…Background A close association between hereditary alpha‐tryptasemia (HAT) and mast cell (MC) disorders has been previously reported. However, the relationship…”
Get full text

Mechanical behaviour and rupture of normal and pathological human ascending aortic wall by García-Herrera, C. M., Atienza, J. M., Rojo, F. J., Claes, E., Guinea, G. V., Celentano, D. J., García-Montero, C., Burgos, R. L.

“…The mechanical properties of aortic wall, both healthy and pathological, are needed in order to develop and improve diagnostic and interventional criteria, and…”
Get full text

Immune-Checkpoint Blockade Opposes CD8 + T-cell Suppression in Human and Murine Cancer by Pfannenstiel, Lukas W, Diaz-Montero, C Marcela, Tian, Ye F, Scharpf, Joseph, Ko, Jennifer S, Gastman, Brian R

“…Immune-checkpoint blockade enhances antitumor responses against cancers. One cancer type that is sensitive to checkpoint blockade is squamous cell carcinoma of…”
Get more information

Recent advances in the understanding of mastocytosis: the role of KIT mutations by Orfao, Alberto, Garcia‐Montero, Andrés C., Sanchez, Laura, Escribano, Luis

“…Mastocytosis is a heterogeneous disorder characterised by the expansion and accumulation of mast cells in different organs and tissues. Mast cell physiology is…”
Get full text

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis by Jawhar, Mohamad, Schwaab, Juliana, Álvarez-Twose, Iván, Shoumariyeh, Khalid, Naumann, Nicole, Lübke, Johannes, Perkins, Cecelia, Muñoz-González, Javier I, Meggendorfer, Manja, Kennedy, Vanessa, Metzgeroth, Georgia, Fabarius, Alice, Pfeifer, Dietmar, Sotlar, Karl, Horny, Hans-Peter, von Bubnoff, Nikolas, Haferlach, Torsten, Cross, Nicholas C P, Hofmann, Wolf-Karsten, Sperr, Wolfgang R, García-Montero, Andrés C, Valent, Peter, Gotlib, Jason, Orfao, Alberto, Reiter, Andreas

“…To develop a risk score for patients with advanced systemic mastocytosis (AdvSM) that integrates clinical and mutation characteristics. The study included 383…”
Get full text

The immunophenotype of mast cells and its utility in the diagnostic work‐up of systemic mastocytosis by Teodosio, Cristina, Mayado, Andrea, Sa´nchez‐Mun~oz, Laura, Morgado, Jose´ M., Jara‐Acevedo, Mari´a, A´lvarez‐Twose, Ivan, Garci´a‐Montero, Andre´s C., Matito, Almudena, Caldas, Caldas, Escribano, Luis, Orfao, Alberto

“…Review of normal/reactive mast cell maturational profiles for the identification of aberrant phenotypes used in the diagnostic work‐up of systemic…”
Get full text

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes by Teodosio, Cristina, MSc, García-Montero, Andrés C., PhD, Jara-Acevedo, María, MSc, Sánchez-Muñoz, Laura, MD, PhD, Álvarez-Twose, Ivan, MD, Núñez, Rosa, MD, Schwartz, Lawrence B., MD, PhD, Walls, Andrew F., PhD, Escribano, Luis, MD, PhD, Orfao, Alberto, MD, PhD

“…Background Systemic mastocytosis (SM) is a heterogeneous group of disorders with distinct clinical and biological behavior. Despite this, little is known about…”
Get full text

A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients by Li, Chuan, Phoon, Yee Peng, Karlinsey, Keaton, Tian, Ye F, Thapaliya, Samjhana, Thongkum, Angkana, Qu, Lili, Matz, Alyssa Joyce, Cameron, Mark, Cameron, Cheryl, Menoret, Antoine, Funchain, Pauline, Song, Jung-Min, Diaz-Montero, C Marcela, Tamilselvan, Banumathi, Golden, Jackelyn B, Cartwright, Michael, Rodriguez, Annabelle, Bonin, Christopher, Vella, Anthony, Zhou, Beiyan, Gastman, Brian R

“…Immune checkpoint inhibitor (ICI) therapy continues to revolutionize melanoma treatment, but only a subset of patients respond. Major efforts are underway to…”
Get full text

T‐cell immune profile in blood of systemic mastocytosis: Association with disease features by Pérez‐Pons, Alba, Teodosio, Cristina, Jara‐Acevedo, María, Henriques, Ana, Navarro‐Navarro, Paula, García‐Montero, Andrés C., Álvarez‐Twose, Iván, Lecrevisse, Quentin, Fluxa, Rafael, Sánchez‐Muñoz, Laura, Caldas, Carolina, Pozo, Julio, Martín, Silvia, Sanfeliciano, Teresa Contreras, Pedreira, Carlos E., Botafogo, Vitor, González‐López, Oscar, Mayado, Andrea, Orfao, Alberto

“…Background Systemic mastocytosis (SM) is a heterogeneous disease characterized by an expansion of KIT‐mutated mast cells (MC). KIT‐mutated MC display activated…”
Get full text

Immunobiology of Melanoma by Phoon, Yee Peng, Tannenbaum, Charles, Diaz-Montero, C. Marcela

“…Despite the ability of immune-based interventions to dramatically increase the survival of patients with melanoma, a significant subset fail to benefit from…”
Get full text

Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis by Muñoz-González, Javier I., Álvarez-Twose, Iván, Jara-Acevedo, María, Henriques, Ana, Viñas, Esther, Prieto, Carlos, Sánchez-Muñoz, Laura, Caldas, Carolina, Mayado, Andrea, Matito, Almudena, Dasilva-Freire, Noelia, Orfao, Alberto, García-Montero, Andrés C.

“…Indolent systemic mastocytosis (ISM) patients have a normal life expectancy, except in the 5% to 10% of cases that progress to more advanced SM (advSM), which…”
Get full text

Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy by McCrae, Keith R., Swaidani, Shadi, Diaz-Montero, C. Marcela, Khorana, Alok A.

“…Cancer immunotherapy has emerged as one of the most important new treatments for cancer in many years, moving rapidly to front-line therapy for several…”
Get full text